Seelos Therapeutics Company Leadership
| SEEL Stock | USD 0.34 0.01 3.03% |
Seelos Therapeutics' insiders are aggressively buying. The analysis of insiders' sentiment of trading Seelos Therapeutics stock suggests that most insiders are extremely bullish at this time. Seelos Therapeutics employs about 15 people. The company is managed by 7 executives with a total tenure of roughly 35 years, averaging almost 5.0 years of service per executive, having 2.14 employees per reported executive.
Seelos Therapeutics' Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2022-06-01 | Daniel J O'connor | Acquired 533 @ 18.3 | View | ||
| 2022-03-31 | Raj Mehra | Acquired 2222 @ 25.5 | View |
Monitoring Seelos Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Seelos |
Seelos Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (1.7975) % which means that it has lost $1.7975 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.842) %, meaning that it created substantial loss on money invested by shareholders. Seelos Therapeutics' management efficiency ratios could be used to measure how well Seelos Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is expected to rise to 1.27 this year, although the value of Return On Tangible Assets are projected to rise to (6.64). At this time, Seelos Therapeutics' Intangible Assets are quite stable compared to the past year. Intangibles To Total Assets is expected to rise to 0.21 this year, although the value of Non Current Assets Total will most likely fall to about 14.2 K.Common Stock Shares Outstanding is expected to rise to about 5.1 M this year, although the value of Net Loss is projected to rise to (62.9 M).
Seelos Therapeutics Workforce Comparison
Seelos Therapeutics is rated below average in number of employees category among related companies. The total workforce of Health Care industry is at this time estimated at about 2,177. Seelos Therapeutics maintains roughly 15.0 in number of employees contributing less than 1% to equities under Health Care industry.
Seelos Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Seelos Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Seelos Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Seelos Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Smith Sandford D over two months ago Purchase by Smith Sandford D of 18200 shares of Seelos Therapeutics | ||
Richard Pascoe over three months ago Acquisition by Richard Pascoe of 1666 shares of Seelos Therapeutics subject to Rule 16b-3 |
Seelos Therapeutics Notable Stakeholders
A Seelos Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Seelos Therapeutics often face trade-offs trying to please all of them. Seelos Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Seelos Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Gopal Krishna | Head Operations | Profile | |
| Michael Golembiewski | Chief Officer | Profile | |
| Kimberly Farrand | Senior Operations | Profile | |
| Raj JD | Chairman, Founder | Profile | |
| Anthony Marciano | Chief Officer | Profile | |
| Karen Fusaro | Senior Operations | Profile | |
| Tim MD | Chief Officer | Profile |
About Seelos Therapeutics Management Performance
The success or failure of an entity such as Seelos Therapeutics often depends on how effective the management is. Seelos Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Seelos management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Seelos management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (6.99) | (6.64) | |
| Return On Capital Employed | 1.21 | 1.27 | |
| Return On Assets | (6.99) | (6.64) | |
| Return On Equity | 1.13 | 1.07 |
The data published in Seelos Therapeutics' official financial statements usually reflect Seelos Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Seelos Therapeutics. For example, before you start analyzing numbers published by Seelos accountants, it's critical to develop an understanding of what Seelos Therapeutics' liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Seelos Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Seelos Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Seelos Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Seelos Therapeutics. Please utilize our Beneish M Score to check the likelihood of Seelos Therapeutics' management manipulating its earnings.
Seelos Therapeutics Workforce Analysis
Traditionally, organizations such as Seelos Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Seelos Therapeutics within its industry.Seelos Therapeutics Manpower Efficiency
Return on Seelos Therapeutics Manpower
| Revenue Per Employee | 146.9K | |
| Revenue Per Executive | 314.7K | |
| Net Loss Per Employee | 2.5M | |
| Net Loss Per Executive | 5.4M |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Seelos Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. For more information on how to buy Seelos Stock please use our How to buy in Seelos Stock guide.Note that the Seelos Therapeutics information on this page should be used as a complementary analysis to other Seelos Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Complementary Tools for Seelos Stock analysis
When running Seelos Therapeutics' price analysis, check to measure Seelos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Seelos Therapeutics is operating at the current time. Most of Seelos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Seelos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Seelos Therapeutics' price. Additionally, you may evaluate how the addition of Seelos Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |
Is Seelos Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Seelos Therapeutics. If investors know Seelos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Seelos Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.73) | Revenue Per Share 0.45 | Return On Assets (1.80) | Return On Equity (5.84) |
The market value of Seelos Therapeutics is measured differently than its book value, which is the value of Seelos that is recorded on the company's balance sheet. Investors also form their own opinion of Seelos Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Seelos Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Seelos Therapeutics' market value can be influenced by many factors that don't directly affect Seelos Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Seelos Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Seelos Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Seelos Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.